Use of spla2 activity for the diagnosis of a cardiovascular event
Номер патента: EP2046977A1
Опубликовано: 15-04-2009
Автор(ы): Alain Tedgui, Joëlle Benessiano, Ziad Mallat
Принадлежит: Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM
Опубликовано: 15-04-2009
Автор(ы): Alain Tedgui, Joëlle Benessiano, Ziad Mallat
Принадлежит: Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM
Реферат: The present invention relates a method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, comprising: - determining the sPLA2 activity of said patient as a first risk marker - determining at least the value of a second risk marker chosen among CRP level, IgM IC of apo B 100 level or IgM MDA-LDL level - determining the ratio (odds ratio) between the value of the sPLA2 activity and the value of the second risk marker and comparing it to a predetermined odds ratio, said odds ratio compared to said predetermined odds ratio being indicative of an increased risk of mortality or of a cardiac and /or vascular event. The present invention further relates a new micro method adaptation for automated fluorimetric measurement of serum secretory phospholipase A2.
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)
Номер патента: US12105098B2. Автор: Beth MCQUISTON,Raj CHANDRAN,Saul A. Datwyler. Владелец: ABBOTT LABORATORIES. Дата публикации: 2024-10-01.